Press release
Cytomegalovirus Infection Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics
"Cytomegalovirus Infection Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus Infection Market.
The Cytomegalovirus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cytomegalovirus Infection Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Cytomegalovirus Infection treatment therapies with a considerable amount of success over the years.
*
Cytomegalovirus Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus Infection treatment
*
Emerging Cytomegalovirus Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus Infection market in the coming years.
*
In March 2025, ACTG, an international clinical trials network dedicated to HIV and other infectious diseases, presented encouraging results from a study examining the impact of treating asymptomatic cytomegalovirus (CMV) in individuals living with HIV. The findings suggest that CMV suppression may enhance immune function and overall physical health. Data from study A5383 were shared during an oral presentation titled, "Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV," at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.
*
In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Helocyte, Inc., announced that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial. The study aims to assess the effectiveness of Triplex, a cytomegalovirus (CMV) vaccine, when given to human leukocyte antigen (HLA)-matched related stem cell donors to reduce CMV occurrences in patients undergoing hematopoietic stem cell transplantation (HSCT).
*
In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrated superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
Cytomegalovirus Infection Overview
Cytomegalovirus Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.
Get a Free Sample PDF Report to know more about Cytomegalovirus Infection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Cytomegalovirus Infection Drugs Under Different Phases of Clinical Development Include:
*
Research programme: antiviral therapeutics TSRL
*
SYN002: Synklino
*
Posoleucel: AlloVir
*
mRNA-1647: Moderna
*
CMV TCR T cell therapy: China Immunotech
*
NPC-21: Nobelpharma
*
HB-101: Hookipa Biotech GmbH
*
Cytomegalovirus immune globulin: Biotest
*
Posoleucel: AlloVir
*
VBI-1501A: VBI Vaccines
*
LTV 20: Lion TCR
*
Maribavir: Shire
*
V160: Merck Sharp & Dohme
*
Maribavir: Takeda
*
Valganciclovir: CSL Behring
*
Brincidofovir: Chimerix
*
Everolimus: Novartis
*
HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus Infection Route of Administration
Cytomegalovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intranasal
*
Intrathecal
*
Intravenous
*
Oral
*
Oral/Intravenous
*
Parenteral
*
Subcutaneous
*
Subcutaneous/Intramuscular
*
Transdermal
Cytomegalovirus Infection Molecule Type
Cytomegalovirus Infection Products have been categorized under various Molecule types, such as
*
Antisense oligonucleotide
*
Gene therapy
*
Hormones
*
Neuropeptides
*
Oligonucleotides
*
Small Molecule
*
Triglyceride
Cytomegalovirus Infection Pipeline Therapeutics Assessment
*
Cytomegalovirus Infection Assessment by Product Type
*
Cytomegalovirus Infection By Stage and Product Type
*
Cytomegalovirus Infection Assessment by Route of Administration
*
Cytomegalovirus Infection By Stage and Route of Administration
*
Cytomegalovirus Infection Assessment by Molecule Type
*
Cytomegalovirus Infection by Stage and Molecule Type
DelveInsight's Cytomegalovirus Infection Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Cytomegalovirus Infection product details are provided in the report. Download the Cytomegalovirus Infection pipeline report to learn more about the emerging Cytomegalovirus Infection therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Cytomegalovirus Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus Infection are - Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.
Cytomegalovirus Infection Pipeline Analysis:
The Cytomegalovirus Infection pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
*
Cytomegalovirus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus Infection drugs and therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Cytomegalovirus Infection Pipeline Market Drivers
*
Increasing Prevalence of Cytomegalovirus Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus Infection Market.
Cytomegalovirus Infection Pipeline Market Barriers
*
However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus Infection Market growth.
Scope of Cytomegalovirus Infection Pipeline Drug Insight
*
Coverage: Global
*
Key Cytomegalovirus Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
*
Key Cytomegalovirus Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
*
Cytomegalovirus Infection Therapeutic Assessment: Cytomegalovirus Infection current marketed and Cytomegalovirus Infection emerging therapies
*
Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection market drivers and Cytomegalovirus Infection market barriers
Request for Sample PDF Report for Cytomegalovirus Infection Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Cytomegalovirus Infection Report Introduction
2. Cytomegalovirus Infection Executive Summary
3. Cytomegalovirus Infection Overview
4. Cytomegalovirus Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus Infection Pipeline Therapeutics
6. Cytomegalovirus Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus Infection Mid Stage Products (Phase II)
8. Cytomegalovirus Infection Early Stage Products (Phase I)
9. Cytomegalovirus Infection Preclinical Stage Products
10. Cytomegalovirus Infection Therapeutics Assessment
11. Cytomegalovirus Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus Infection Key Companies
14. Cytomegalovirus Infection Key Products
15. Cytomegalovirus Infection Unmet Needs
16 . Cytomegalovirus Infection Market Drivers and Barriers
17. Cytomegalovirus Infection Future Perspectives and Conclusion
18. Cytomegalovirus Infection Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-infection-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-merck-sharp-dohme-llc-chimerix-vbi-vaccines-atara-biotherapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus Infection Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics here
News-ID: 4140357 • Views: …
More Releases from ABNewswire
ABSSSI Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Bacterial Skin and Skin-Structure Infection pipeline constitutes 2+ key companies continuously working towards developing 2+ Acute Bacterial Skin and Skin-Structure Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Acute Bacterial Skin and Skin-Structure Infection Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario…
Kishin Amerson Creates Revenue-Driven AI SEO, The New Standard for AI Search Pos …
Kishin Amerson has introduced Revenue-Driven AI SEO, a framework helping high-ticket online businesses secure top placement in AI-generated search results and turn visibility into revenue.
In the rapidly evolving landscape of digital marketing, AI-driven search is transforming how buyers discover and evaluate businesses. Revenue-Driven AI SEO , created by Kishin Amerson, is a strategic framework built to help high-ticket online businesses adapt to this shift by clearly understanding and applying the…
San Bernardino CPS Victory: Mother Wins Court Battle to Have Child Placed with M …
A San Bernardino county mother successfully challenged the Department of Social Services' initial refusal to place her removed child with the maternal grandmother. With legal help from attorney Walter Shaw, the court ruled in favor of the mother and placed her child with the maternal grandmother-a decision that highlights the importance of keeping children within family networks during child welfare cases.
In a significant legal victory, a San Bernardino County judge…
Follicular Lymphoma Market Trends Point to Steady Growth Ahead by 2034, DelveIns …
The Key Follicular Lymphoma Companies in the market include - Roche, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others.
FelveInsight's "Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market…
More Releases for Cytomegalovirus
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Cytomegalovirus Solutions Soar: Cytomegalovirus Treatment Market Targets US$ 326 …
The Cytomegalovirus (CMV) Treatment Market stands at the forefront of addressing a formidable viral adversary that often operates under the radar. Cytomegalovirus, a member of the herpesvirus family, can pose serious threats to individuals with weakened immune systems, such as transplant recipients and those living with HIV. As a result, the development of effective treatments has become a critical endeavor in the realm of infectious diseases.
In 2022, the global cytomegalovirus…
Cytomegalovirus Treatment Market Will Generate Record Revenue by 2029
The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%-56.0% in SOT recipients and 30.0%-70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in…
Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28
The global cytomegalovirus diagnostics market size was valued at USD 73.6 million in 2021, growing at a CAGR of 6.1% during the forecast period 2022-28. A common herpesvirus called cytomegalovirus can produce a wide range of symptoms, from little to no symptoms to fever and tiredness to severe symptoms affecting the brain, eyes, and other internal organs. Plasma, sperm, saliva, urinalysis, and breast milk can all be used as…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
Cytomegalovirus Assay Market Latest Report with Forecast 2017-2027
Global Cytomegalovirus Assay Market: Snapshot
CMV diagnostics turn out to be exceptionally basic for immunocompromised people and pregnant ladies as well. Cytomegaloviruses are one of the main sources of mental hindrance in kids and viral diseases. A cytomegalovirus can cause asymptomatic contaminations in immunocompromised people and can be transmitted to the embryo while pregnancy from his mom, which may show essential or intermittent disease. Hence, it require a proper analysis of…
